Cellular constituents of immune escape within the tumor microenvironment
- PMID: 22721837
- PMCID: PMC6327310
- DOI: 10.1158/0008-5472.CAN-11-4094
Cellular constituents of immune escape within the tumor microenvironment
Abstract
Established tumors are complex masses that contain not only neoplastic cells but also nontransformed cellular elements such as stromal cells, the neovasculature, and the full gamut of immune cells. However, evidence suggests that, unlike cells found in lymphoid organs that productively respond to acute infections, immune cells in tumors are dysregulated and functionally impaired. Tumor masses can contain regulatory lymphocytes, myeloid-derived suppressor cells, alternatively activated macrophages, and dendritic cells. Ablation or reprogramming of this aberrant microenvironment might dramatically augment cancer therapies, and this strategy is currently being deployed in a variety of clinical trials. A better understanding of the cellular constituents of tumors and the mechanisms involved in immune evasion may help guide the next generation of innovative cancer immunotherapies.
©2012 AACR.
Conflict of interest statement
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Figures
Similar articles
-
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.J Clin Invest. 2011 Dec;121(12):4746-57. doi: 10.1172/JCI58814. Epub 2011 Nov 7. J Clin Invest. 2011. PMID: 22056381 Free PMC article.
-
CCL21 Programs Immune Activity in Tumor Microenvironment.Adv Exp Med Biol. 2020;1231:67-78. doi: 10.1007/978-3-030-36667-4_7. Adv Exp Med Biol. 2020. PMID: 32060847 Review.
-
Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.Int J Mol Sci. 2021 Sep 24;22(19):10268. doi: 10.3390/ijms221910268. Int J Mol Sci. 2021. PMID: 34638609 Free PMC article. Review.
-
Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression.Front Immunol. 2021 May 18;12:624725. doi: 10.3389/fimmu.2021.624725. eCollection 2021. Front Immunol. 2021. PMID: 34084160 Free PMC article.
-
Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.Am J Physiol Cell Physiol. 2015 Nov 1;309(9):C569-79. doi: 10.1152/ajpcell.00207.2015. Epub 2015 Aug 26. Am J Physiol Cell Physiol. 2015. PMID: 26310815 Free PMC article. Review.
Cited by
-
Joint analysis of mutational and transcriptional landscapes in human cancer reveals key perturbations during cancer evolution.Genome Biol. 2024 Mar 8;25(1):65. doi: 10.1186/s13059-024-03201-1. Genome Biol. 2024. PMID: 38459554 Free PMC article.
-
GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy.J Exp Clin Cancer Res. 2024 Mar 1;43(1):66. doi: 10.1186/s13046-024-02993-1. J Exp Clin Cancer Res. 2024. PMID: 38424590 Free PMC article. Review.
-
The current landscape of the antimicrobial peptide melittin and its therapeutic potential.Front Immunol. 2024 Jan 22;15:1326033. doi: 10.3389/fimmu.2024.1326033. eCollection 2024. Front Immunol. 2024. PMID: 38318188 Free PMC article. Review.
-
ADP-Ribosylation Factor 6 Pathway Acts as a Key Executor of Mesenchymal Tumor Plasticity.Int J Mol Sci. 2023 Oct 5;24(19):14934. doi: 10.3390/ijms241914934. Int J Mol Sci. 2023. PMID: 37834383 Free PMC article. Review.
-
Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy.Bioact Mater. 2023 Sep 6;31:440-462. doi: 10.1016/j.bioactmat.2023.08.022. eCollection 2024 Jan. Bioact Mater. 2023. PMID: 37701452 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
